Release date: 2014-05-19
According to the latest research data, the new cancer detection guideline introduced this year in the United States will bring about $9.3 billion in medical costs in CT testing in the next five years, which means a huge market for the CT testing industry.
In the guidelines released earlier this year, the American Cancer Society (ACS) and the US Preventive Services Working Group (USPSTF) stated that CT testing can prevent 20% of lung cancer patients from dying compared with normal X-ray examinations.
A report released Wednesday by the Fred Hutchinson Cancer Research Center in Seattle predicts that an additional 20% of high-risk populations will receive low-dose CT imaging in the next five years, which is equivalent to a medical cost of $9.3 billion, of which $5.6 billion will be used for CT testing. $1.1 billion is for diagnosis and $2.6 billion will be used for cancer patient care.
Lung cancer is one of the most deadly cancers. In the United States, more than 150,000 people die of cancer each year, and 3 out of every 10 cancer deaths are lung cancer patients, with a five-year survival rate of less than 16%.
The companies involved in the CT testing concept in the A-share market mainly include Neusoft Group (600718.SH). The NeuViz16 multi-slice spiral CT developed by the company's Neusoft Medical Systems Co., Ltd. was registered and listed by the US Food and Drug Administration (FDA) in 2009. .
Source: Great Wisdom
Naphazoline Hydrochloride Intermediate,Naphazoline Hydrochloride,Naphazoline Hydrochloride Api,Naphazoline Hydrochloride Cas 90719-32-7
Shandong Bolode Bio-technology Co., Ltd. , https://www.bldpharma.com